Engineered myeloid precursors differentiate into osteoclasts and resorb heterotopic ossification in mice.

ABSTRACT:

Introduction

Heterotopic ossification (HO) occurs following orthopedic trauma, spinal cord injuries, brain trauma and limb amputations. Once symptomatic, HO causes pain, limited mobility and decreased quality of life. Current treatments are limited and have significant complications with high recurrence rates, underscoring the need for improved therapeutic interventions. Osteoclasts (OCs) are physiological bone resorptive cells that secrete enzymes and protons to degrade bone.

Methods

In this study, we describe the use of genetically engineered OCs as a novel cell therapy approach to treat HO. Inducible, engineered myeloid precursors (iRANK cells) treated with a chemical inducer of dimerization (CID) differentiated into TRAP⁺ multinucleated OCs and resorbed minera

SUBMITTER: Rementer C 

PROVIDER: S-EPMC11620886 | biostudies-literature | 2024

REPOSITORIES: biostudies-literature